比较极低碳水化合物饮食与中等碳水化合物餐盘法饮食治疗2型糖尿病的随机对照试验方案:LEGEND(糖尿病营养生活方式教育)试验
LEGEND试验为两中心随机对照试验,计划纳入180例2型糖尿病成人,随机接受20次团体饮食与生活方式干预,分别教授极低碳水化合物饮食或中等碳水化合物餐盘法饮食。主要结局为HbA1c,次要结局包括炎症、体重、降糖药物变化、血脂、骨骼代谢和体成分,随访至12个月。
要点
- LEGEND试验比较极低碳水化合物饮食与中等碳水化合物餐盘法饮食对2型糖尿病血糖控制的影响。
- 计划纳入180例成人2型糖尿病受试者,随机分组接受20次团体饮食与生活方式干预。
- 主要结局为HbA1c,次要结局包括炎症、体重、降糖药物变化、血脂、骨骼代谢和体成分。
核心结论
- 该试验旨在通过为期一年的评估,比较极低碳水化合物饮食与中等碳水化合物餐盘法饮食对2型糖尿病的影响,为营养管理提供不同碳水化合物摄入水平的潜在获益与不良效应数据。
研究设计与样本
- LEGEND试验为两中心随机对照试验,计划招募180例2型糖尿病成人。
- 受试者随机接受20次团体饮食与生活方式干预,分别教授极低碳水化合物饮食或中等碳水化合物餐盘法饮食。
- 在入组时以及4个月和12个月后评估受试者。
主要发现
- 主要结局为HbA1c。
- 次要结局包括炎症(高敏C反应蛋白)、体重、降糖药物变化、血脂(小颗粒LDL、HDL、甘油三酯)、骨骼代谢(双能X线吸收法测定的骨密度及骨转换标志物血清I型前胶原N端前肽和血清I型胶原C端肽)和体成分(体脂百分比、瘦体重百分比)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal carbohydrate intake is an important and controversial area in the nutritional management of type 2 diabetes. Some evidence indicates that reducing overall carbohydrate intake with a low- or very low-carbohydrate eating plan can improve glycemic control compared to following eating plans that involve greater carbohydrate intake. However, critical knowledge gaps currently prevent clear recommendations about carbohydrate intake levels. METHODS: The LEGEND (Lifestyle Education about Nutrition for Diabetes) Trial aims to compare a very low-carbohydrate diet to a moderate-carbohydrate plate-method diet for glycemic control in adults with type 2 diabetes. This two-site trial plans to recruit 180 adults with type 2 diabetes. We will randomize participants to either a 20-session group-based diet and lifestyle intervention that teaches either a very low-carbohydrate diet or a moderate-carbohydrate plate-method diet. We will assess participants at study entry and 4 and 12 months later. The primary outcome is HbA1c, and secondary outcomes include inflammation (high sensitivity C-reactive protein), body weight, changes in diabetes medications, lipids (small particle LDL, HDL, triglycerides), skeletal metabolism (bone mineral density from dual-energy x-ray absorptiometry and bone turnover markers serum procollagen type I N propeptide and serum C-terminal telopeptide of type I collagen), and body composition (percent body fat, percent lean body mass). DISCUSSION: The LEGEND trial is a randomized controlled trial to assess optimal carbohydrate intake in type 2 diabetes by evaluating the effects of a very low-carbohydrate diet vs. a moderate-carbohydrate plate-method diet over a year-long period. The research addresses important gaps in the evidence base for the nutritional management of type 2 diabetes by providing data on potential benefits and adverse effects of different levels of carbohydrate intake. TRIAL REGISTRATION: ClinicalTrials.gov NCT05237128. Registered on February 11, 2022.
引用
- Saslow LR, Eslamian A, Moran P, et al. Protocol for a randomized controlled trial comparing a very low-carbohydrate diet or moderate-carbohydrate plate-method diet for type 2 diabetes: the LEGEND (Lifestyle Education about Nutrition for Diabetes) trial. Trials. 2023. PMID: 37475033. doi:10.1186/s13063-023-07512-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。